RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Novo-Nordisk (NVO)

NYSE:NVO

Novo-Nordisk (NVO)

47.41
-0.01 (0.02%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
265 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 30 opinions in the last 12 months.

Novo-Nordisk (NVO) is facing significant challenges within the pharmaceutical space, particularly in the competitive weight-loss and diabetes markets, where Eli Lilly (LLY) appears to have the upper hand. Many experts express concern over NVO's declining market share and the company's reliance on its weight-loss drug, which is under pressure from generic competition and pricing wars. The stock's technical indicators show a downtrend, with analysts mentioning that NVO has had to cut guidance multiple times and is seen as a potential value trap. While there are long-term growth prospects, especially regarding obesity and diabetes treatments, most analysts suggest caution in the short term and a preference for LLY over NVO. The consensus is that while there may be some value, NVO's short-term outlook is uncertain with potential for more downward pressure.

consensus icon
Consensus
Negative
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
HOLD

Novo-Nordisk(NVO)

Apr 02, 2013

Largest manufacturer of insulin globally and has been taking share from Eli Lilly (LLY-N) for years. Stock sold off because it had problems getting FDA approval for a new type of diabetes drug that has been approved in Europe and Japan.

Photo of Charles LannonCharles Lannon
Owned
Unlock Rating
$164.35

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Apr 11, 2012
(A Top Pick March 31/11. Up 17.16%.) Biggest product is insulin. Type 2 diabetics is expected to grow by 50% over the next 20 years. Have new products coming out.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$144.45

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Mar 31, 2011
(Buys on Danish exchange for a better bid/offer spread and more liquidity than with ADRs.) Largest insulin manufacturer pharmaceutical globally. Diabetic cases expected to rise 50% over the next 20years, particularly in India and China. Very good at patent protection. Trading at a discount to where its growth rate is expected.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$125.23

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Nov 29, 2010
(A Top Pick Dec 29/09. Up 61.3%.) Yield of 1%. Still a Buy.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$100.48

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PARTIAL BUY

Novo-Nordisk(NVO)

Apr 29, 2010
Danish pharmaceutical company. Top market share in insulin. Expensive health-care stock but unique in that it doesn't face a patent cliff. Long-term growth profile. With financial problems in Europe, space your purchases over 6 months with 2 or 3 Buys.
Photo of Charles LannonCharles Lannon
Owned
Unlock Rating
$82.44

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Dec 29, 2009
Has been more stable than the rest of the pharmaceuticals. Is an insulin producer, which pretty much dominates the market. Diabetic cases will rise 2-4 hundred million over the next 20 years, predominantly because Indians tend to be very susceptible to it. Return on capital is very high – 25-30% range. Very little debt. Dividend increased almost 20% last year.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$64.56

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Jun 09, 2008
Insulin maker out of Denmark. Good pipeline and good patent protection. Diabetic patients will double over the next 10 to 20 years.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$67.03

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Oct 20, 2006
Largest insulin manufacturer in the world. Also makes a haemophiliac medicine that provides clotting during surgery. About to get FDA approval for an application for stroke victims and gunshot wounds.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$77.47

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Sep 14, 2006
(A Top Pick Aug 3/05. Up 23%.) Added more salespeople in the US. Sales on the insulin side are growing. Still a lot of growth coming.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$74.63

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Jul 26, 2006
His favourite pharmaceutical. 1.5% dividend and dividend growth has been 20% over the last 5 years. Largest supplier of insulin in the world. Rate of diabetes continues to rise. Cheap at this price.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$62.29

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Feb 23, 2006
Past Top pick. Insulin demain is growing over the next 20 years. It's still a long term investment.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$58.16

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Nov 03, 2005
Manufactures insulin. Human insulin is in huge demand and they control the market. Good earnings last quarter. Good price.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$52.53

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Aug 03, 2005
The growth in cases of diabetes in the next 20 years is expected to double from 3 to 6 hundred million globally. The stock had fallen from $58 to the low $50's because their drug was going to be delayed. Stock is now getting interesting.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$54.70

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Jun 08, 2004
(A top pick Dec 1/03. Up 30%.) The cases of diabetics is expected to double.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$47.89

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Dec 11, 2003
In pharmaceuticals, they devote most money per revenue into R&D. Demographically, feels that China and India will be strong future markets.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$37.33

Stock price when the opinion was issued

$47.41

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 181 to 195 of 202 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica